Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2120MR)

This product GTTS-WQ2120MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ2120MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15805MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ9700MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ9552MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ4467MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ6954MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ13270MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ7480MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC-1008
GTTS-WQ3751MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY-1093884
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW